Home LiteratureArticle Details
PMID: 9032334 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution?

Journal of virology ·Vol. 71 ·No. 3 ·1997-03-00 ·Pages 2023-30

Lukashov VV, Goudsmit J

Abstract

We and others have shown that in individual human immunodeficiency virus type 1 (HIV-1) infection, the adaptive evolution of HIV-1 is influenced by host immune competence. In this study, we tested the hypothesis that in addition to selective forces operating within the host, transmission bottlenecks have an impact on HIV-1 intrahost evolution. Therefore, we studied the intrahost evolution of the V3 region of the external glycoprotein gp120 of HIV-1 during the 3- and 5-year periods following seroconversion after parenteral versus sexual (male-to-male) transmission in 41 participants of the Amsterdam prospective cohorts of homosexual men (n = 31) and intravenous drug users (IVDUs; n = 10) who were AIDS free and had comparable numbers of CD4+ cells. We observed that HIV-1 strains in homosexual men accumulated over 5 years more nonsynonymous substitutions within the V3 loop than HIV-1 strains in IVDUs as a result of lower rates of nonsynonymous evolution in both the initial 3-year period from seroconversion and the following 2-year period as well as a larger proportion of nonsynonymous back substitutions in IVDUs. The mean numbers of synonymous substitutions did not differ between the two risk groups. Since HIV-1 strains in IVDUs could be distinguished from the viruses of homosexual men based on several nucleotide substitutions of which the most conserved is a synonymous substitution at the tip of the V3 loop (GGC pattern), we studied whether the founder virus population itself has an impact on the intrahost evolution of HIV-1. The mean number of nonsynonymous substitutions accumulated over 5 years within the V3 loop was lower in 10 IVDUs infected by the HIV-1 strains with the GGC signature than in 4 IVDUs infected by HIV-1 strains lacking this pattern, while the mean numbers of synonymous substitutions were similar in the two groups.

MeSH Terms
CD4 Lymphocyte Count Cohort Studies Evolution, Molecular Follow-Up Studies HIV Envelope Protein gp120/genetics HIV Seropositivity/immunology,virology HIV-1/genetics,immunology,isolation & purification Homosexuality, Male Humans Male Mutagenesis Peptide Fragments/genetics Phylogeny Prospective Studies Substance Abuse, Intravenous
Chemicals
HIV Envelope Protein gp120 HIV envelope protein gp120 (305-321) Peptide Fragments
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lukashov V V
Department of Human Retrovirology, University of Amsterdam, The Netherlands.
Goudsmit J
References (38)
38 references, click to expand
  1. Immunologic abnormalities in heroin addiction.
    South Med J. 1974 Feb;67(2):193-7 PMID: 4130051
  2. Human immunodeficiency virus type 1 RNA populations in faeces with higher homology to intestinal populations than to blood populations.
    J Gen Virol. 1996 Oct;77 ( Pt 10):2415-25 PMID: 8887472
  3. Thrombocytopenia and intravenous heroin use.
    Ann Intern Med. 1978 Aug;89(2):207-11 PMID: 677582
  4. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes.
    J Immunol. 1979 Sep;123(3):1068-70 PMID: 224107
  5. Immunoglobulins in heroin users.
    Am J Epidemiol. 1980 Jan;111(1):81-6 PMID: 7352461
  6. Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes.
    J Immunol. 1980 Dec;125(6):2539-43 PMID: 6253568
  7. Estimation of evolutionary distances between homologous nucleotide sequences.
    Proc Natl Acad Sci U S A. 1981 Jan;78(1):454-8 PMID: 6165991
  8. Opiate receptors on lymphocytes and platelets in man.
    Clin Immunol Immunopathol. 1983 May;27(2):240-9 PMID: 6307570
  9. Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression.
    Clin Immunol Immunopathol. 1986 Nov;41(2):254-64 PMID: 3095006
  10. Rapid and simple method for purification of nucleic acids.
    J Clin Microbiol. 1990 Mar;28(3):495-503 PMID: 1691208
  11. Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous.
    Proc Natl Acad Sci U S A. 1990 Dec;87(24):9938-42 PMID: 1702224
  12. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals.
    Virology. 1991 Jun;182(2):802-9 PMID: 2024498
  13. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users.
    AIDS. 1991 Jan;5(1):35-41 PMID: 1829366
  14. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.
    J Virol. 1991 Nov;65(11):5782-9 PMID: 1920616
  15. Sequence ordinations: a multivariate analysis approach to analysing large sequence data sets.
    Comput Appl Biosci. 1992 Feb;8(1):15-22 PMID: 1568121
  16. Prognostic indicators for development of AIDS among intravenous drug users.
    J Acquir Immune Defic Syndr. 1992;5(7):694-700 PMID: 1613668
  17. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.
    J Virol. 1992 Nov;66(11):6547-54 PMID: 1404602
  18. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.
    N Engl J Med. 1992 Dec 10;327(24):1697-703 PMID: 1359411
  19. Signature pattern analysis: a method for assessing viral sequence relatedness.
    AIDS Res Hum Retroviruses. 1992 Sep;8(9):1549-60 PMID: 1457200
  20. Clinical symptoms associated with seroconversion for HIV-1 among misusers of intravenous drugs: comparison with homosexual seroconverters and infected and non-infected intravenous drug misusers.
    BMJ. 1993 Feb 6;306(6874):371-3 PMID: 8461683
  21. Many-trillionfold amplification of single RNA virus particles fails to overcome the Muller's ratchet effect.
    J Virol. 1993 Jun;67(6):3620-3 PMID: 8388514
  22. Genotypic and phenotypic characterization of HIV-1 patients with primary infection.
    Science. 1993 Aug 27;261(5125):1179-81 PMID: 8356453
  23. Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic.
    Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9061-5 PMID: 8415653
  24. Progression of HIV infection among injecting drug users: indications for a lower rate of progression among those who have frequently borrowed injecting equipment.
    AIDS. 1993 Oct;7(10):1363-70 PMID: 8267910
  25. Silent mutation pattern in V3 sequences distinguishes virus according to risk group in Europe.
    AIDS Res Hum Retroviruses. 1994 Mar;10(3):319-20 PMID: 8018394
  26. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays.
    J Virol. 1994 Oct;68(10):6672-83 PMID: 8084001
  27. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes.
    J Virol Methods. 1994 Sep;49(2):157-67 PMID: 7822457
  28. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.
    AIDS Res Hum Retroviruses. 1994 Nov;10(11):1387-400 PMID: 7888192
  29. Isolation of human immunodeficiency virus type 1 (HIV-1) RNA from feces by a simple method and difference between HIV-1 subpopulations in feces and serum.
    J Clin Microbiol. 1995 Mar;33(3):581-8 PMID: 7751361
  30. Exponential increases of RNA virus fitness during large population transmissions.
    Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5841-4 PMID: 7597039
  31. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period.
    J Virol. 1995 Nov;69(11):6911-6 PMID: 7474108
  32. Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men.
    AIDS. 1995 Sep;9(9):1085-92 PMID: 8527083
  33. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission.
    J Virol. 1996 May;70(5):3098-107 PMID: 8627789
  34. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.
    Science. 1996 Apr 26;272(5261):537-42 PMID: 8614801
  35. Consistent risk group-associated differences in human immunodeficiency virus type 1 vpr, vpu and V3 sequences despite independent evolution.
    J Gen Virol. 1996 Apr;77 ( Pt 4):783-92 PMID: 8627267
  36. Evidence for limited within-person evolution of the V3 domain of the HIV-1 envelope in the amsterdam population.
    AIDS. 1996 Jan;10(1):31-7 PMID: 8924249
  37. Evidence for HIV type 1 strains of U.S. intravenous drug users as founders of AIDS epidemic among intravenous drug users in northern Europe.
    AIDS Res Hum Retroviruses. 1996 Aug 10;12(12):1179-83 PMID: 8844022
  38. Immunologic dysfunction in heroin addicts.
    Arch Intern Med. 1974 Dec;134(6):1001-6 PMID: 4433182
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1997-03-00
Pages
2023-30
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC191287
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com